These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9404527

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
    Internist (Berl); 1999 Mar; 40(3 Suppl Gibt Es):1-4. PubMed ID: 10192028
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.
    Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Dorea EL, Bernik M, Hirata RD.
    Clin Chim Acta; 2008 Jul 17; 393(2):119-24. PubMed ID: 18435918
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D.
    Am J Cardiol; 2007 Jun 15; 99(12):1706-1713. PubMed ID: 17560879
    [Abstract] [Full Text] [Related]

  • 10. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M.
    Nutr Metab Cardiovasc Dis; 2002 Feb 15; 12(1):29-35. PubMed ID: 12125227
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
    Z Kardiol; 1999 Mar 15; 88(3 Suppl):1-4. PubMed ID: 10330699
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [What is new? Therapy with lipid lowering agents].
    Internist (Berl); 1997 Nov 15; 38(11 Suppl Therapie):1-8. PubMed ID: 9403084
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve.
    Makkena B, Salti H, Subramaniam M, Thennapan S, Bonow RH, Caira F, Bonow RO, Spelsberg TC, Rajamannan NM.
    J Am Coll Cardiol; 2005 Feb 15; 45(4):631-3. PubMed ID: 15708716
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.